Motif Bio (MTFB) Hits New 52-Week Low at $28.00

Shares of Motif Bio PLC (LON:MTFB) reached a new 52-week low on Monday . The company traded as low as GBX 28 ($0.37) and last traded at GBX 28 ($0.37), with a volume of 346436 shares trading hands. The stock had previously closed at GBX 30 ($0.39).

A number of research firms have commented on MTFB. Peel Hunt restated a “buy” rating on shares of Motif Bio in a research report on Tuesday, August 14th. Northland Securities restated a “buy” rating on shares of Motif Bio in a research report on Tuesday, August 14th.

TRADEMARK VIOLATION NOTICE: “Motif Bio (MTFB) Hits New 52-Week Low at $28.00” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/11/19/motif-bio-mtfb-hits-new-52-week-low-at-28-00.html.

Motif Bio Company Profile (LON:MTFB)

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

See Also: How mutual funds make money

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply